• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Novartis > February 20, 2012

      US FDA Approves Novartis' Gleevec Drug Label Change

      Novartis announces the US Food and Drug Administration (FDA) approval of the label change for its anti-cancer drug Gleevec (imatinib mesylate) to treat CD117-positive gastrointestinal stromal tumor (GIST) patients after surgery. A recent clinical study showed better results such as 54% recurrence-free survival and 55% reduced death risk in gastrointestinal cancer patients with 36 months of Gleevec treatment compared to 12 months of Gleevec treatment.

      With nearly 6000 new cases of GIST reported annually (according to Novartis), FDA’s approval of expanded use of Gleevec drug will help GIST patients to effectively manage the disease.

       

      Share this Article!

    Back to top^